香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司將於2025年10月17日至10 月21日在德國柏林舉辦的2025年歐洲腫瘤內科學會(ESMO)年會上，公佈其新一 代全人源僅重鏈抗CTLA-4抗體普魯蘇拜單抗(HBM4003)聯合替雷利珠單抗治療 微衛星穩定型(MSS)轉移性結直腸癌(mCRC)的II期臨床數據。 初步療效和安全性數據將在2025年ESMO大會的壁報環節進行展示。相關壁報的 具體信息如下： 入選摘要的全文將在線發表於ESMO網站。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 自願公告 於2025年ESMO大會公佈HBM4003聯合替雷利珠單抗治療微衛 星穩定型轉移性結直腸癌的II期臨床數據 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 作出，以告知本公司股東及潛在投資者有 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 （股份代號：2696） 自願公告 地舒單抗生物類似藥HLX14（重組抗RANKL全人單克隆抗體注射液） 獲歐洲藥品管理局(EMA)人用醫藥產品委員會(CHMP)積極審評意見 A. 緒言 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知 本公司股東及潛在投資者本公司最新業務更新。 茲提述本公司於2024年5月24日刊發的公告，內容有關本公司自主研發的 Prolia®與Xgeva® （地舒單抗）生物類似藥HLX14（重組抗RANKL全人單克隆 抗體注射液）（「HLX14」）適用於(1)骨折高風險的絕經後婦女及男性的骨質疏 鬆症治療、(2)骨折高風險的前列腺癌男性與激素消融相關的骨質流失治療、 (3)骨折高風險的成年患者中與長期全身糖皮質激素治療相關骨質流失的治 療、(4)預防成人晚期骨惡性腫瘤的骨相關事件，(5)不可手術切除或手術切除 後可能導致嚴重功能障礙的骨巨細胞瘤患者的治療，包括成 ...

Group 1 - The Hang Seng Index (HSI) is perceived by bullish investors as entering a slow bull market, with all stocks reaching new highs, targeting levels between 25,700 and 26,000 [1] - Bearish investors anticipate a short-term correction to fill the gap below, with a recovery price of 25,900 for overnight bear certificates [1] - Technical analysis indicates a high of 25,735 points, with 15 buy signals and 4 sell signals, suggesting a bullish trend [1] Group 2 - Meituan (03690.HK) is currently trading near the upper Bollinger Band at 134.6 HKD, with a buy signal and resistance levels at 137.7 HKD and 147.6 HKD [3] - The closing price is 134 HKD, with a call option exercise price of 178.98 HKD, indicating a potentially high entry point for investors [3] - Investors are advised to consider options with exercise prices closer to the current market price to mitigate risks associated with high exercise prices [3] Group 3 - Pop Mart (09992.HK) shows a weak recent trend, with a closing price near the middle Bollinger Band at 255.8 HKD and a buy signal, though not a strong buy [5] - Resistance levels are identified at 263 HKD and 273 HKD, with a call option exercise price of 225 HKD providing a defensive position for investors [5] - Investors are encouraged to compare the terms of options when selecting products to manage risk effectively [5] Group 4 - WuXi Biologics (02269.HK) is viewed positively with a strong buy signal, facing a resistance level at 31.1 HKD and 33.3 HKD [8] - Investors are optimistic about the stock's potential to break through the 30 HKD level, with a target price of 46 HKD [8] Group 5 - Hua Hong Semiconductor (01347.HK) is under observation for its structural stability, with a target price of 40.6 HKD [11] - The stock is currently showing a strong buy signal, indicating positive sentiment among investors [11] Group 6 - NIO Inc. (09866.HK) is experiencing a slight downward trend, with the stock price near the upper Bollinger Band at 38.99 HKD [14] - The stock maintains an overall upward trend with 14 buy signals and 6 sell signals, suggesting cautious optimism [14] - Resistance levels are set at 41.7 HKD and 47.3 HKD, while support levels are at 33.7 HKD and 29.9 HKD for put options [14]

Market Performance - The Hang Seng Index (HSI) rose by 408 points or 1.6%, closing at 25,538 points, marking a three-year high and a four-day consecutive increase[1] - The Hang Seng Tech Index increased by 138 points or 2.5%, closing at 5,745 points[1] - The total trading volume in Hong Kong was 333.067 billion HKD[1] Economic Indicators - The People's Bank of China conducted a 150.5 billion CNY reverse repurchase operation at a steady rate of 1.4%[1] - The CNY/USD midpoint rose by 46 pips to 7.1414, the highest level since November 6 of the previous year[1] A-Share Market - The Shanghai Composite Index (SSE) gained less than 1 point or 0.01%, closing at 3,582 points with a trading volume of 857.05 billion CNY[1] - The Shenzhen Component Index fell by 40 points or 0.4%, closing at 11,059 points, with a trading volume of 1.01 trillion CNY[1] - The ChiNext Index decreased by less than 1 point or 0.01%, closing at 2,310 points, with a trading volume of 448.7 billion CNY[1] Trade Agreements - The EU and the US are reportedly close to an agreement to impose a 15% tariff on most products, which led to a rise in US stock markets[2] - The Dow Jones Industrial Average increased by 507 points or 1.1%, reaching 45,016 points, near its historical high[2] - The S&P 500 index rose by 49 points or 0.8%, closing at 6,358 points, marking the 12th record high this year[2] Corporate Earnings - WuXi Biologics (02269.HK) expects a 16% year-on-year increase in revenue for the first half of the year, with a gross margin improvement of approximately 3.6%[3] - Profit attributable to equity shareholders is projected to grow by about 54% year-on-year, with adjusted net profit expected to increase by around 11%[3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 自願公告 HLX22（重組人源化抗HER2單克隆抗體注射液）聯合 曲妥珠單抗和化療(XELOX)對比曲妥珠單抗和化療(XELOX) 聯合或不聯合帕博利珠單抗 一線治療HER2陽性局部晚期或轉移性胃食管交界部和胃癌的 國際多中心3期臨床研究完成美國首例患者給藥 A. 緒言 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知 本公司股東及潛在投資者本公司最新業務更新。 本公司董事會（「董事會」）欣然宣布，近日，一項HLX22（重組人源化抗 HER2單克隆抗體注射液）（「HLX22」）聯合曲妥珠單抗和化療(XELOX)對比 曲妥珠單抗和化療(XELOX)聯合或不聯合帕博利珠單抗一線治療人類表皮 生長因子受體2(HER2)陽性局部晚 ...

Group 1: Market Sentiment and Technical Analysis - Investors are divided on the Hang Seng Index (HSI), with bullish investors entering at 24,000 points and bearish investors expecting a drop to the same level, deploying bear certificates with a redemption price of 24,888 [1] - Technical analysis indicates a "buy" signal for the HSI, with the first resistance level at approximately 24,600 points, and a potential upward test towards 25,000 points if this level is breached [1] - Investors are advised to choose bear certificates with redemption prices above the second resistance level of 25,000 to avoid immediate redemption risks, even if it means sacrificing some leverage [1] Group 2: Company-Specific Insights - WuXi Biologics (02269.HK) shows a temporary "buy" signal with 15 buy signals and no sell signals, but there are 9 neutral signals indicating caution; resistance levels are at 28.5 and 29.5 [3] - WuXi AppTec (02359.HK) has a "buy" signal with 14 buy signals and 4 sell signals, indicating potential upward movement with short-term resistance at 98 and 99.6 [6] - Trip.com Group (09961.HK) has a "strong buy" signal after a rebound from 434.2 to 499.8, with resistance levels at 505 and 531 [9] - AIA Group (01299.HK) shows a mixed outlook with 15 buy signals and 3 sell signals; resistance levels are at 71.6 and 73.8, suggesting caution before challenging 75 [11] - JD.com (09618.HK) is experiencing bearish sentiment with a "sell" signal, and investors are advised to wait for a drop to 115 before considering entry [14]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 自願公告 有關恩凱賽藥的A+++輪融資 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）按自 願基準作出，以知會本公司股東（「股東」）及潛在投資者有關本集團的最新業務進 展。 本公司董事會（「董事會」）欣然宣佈，本公司所投資的公司上海恩凱細胞技術有限 公司（「恩凱賽藥」）近日已完成A+++輪融資，本輪融資由多名投資者參與，融資 近人民幣1億元。所得款項將用於推進其核心NK細胞療法產品候選藥物的臨床試 驗，並支持其產品管線的開發。 此次成功融資反映出恩凱賽藥在NK細胞療法開發領域持續取得突破，表明投資人 對其創新免疫治療平台充滿信心，所獲資金將為加速臨床轉化提供重要支撐。 關於恩凱賽藥 恩凱賽藥是一家生物科技公司，專注於NK細胞療法創新技術的研發。2024年， ...

Market Overview - The Hang Seng Index is constrained by the March high of 24,874 points, with expectations of new financial policies from mainland China to stabilize the market, including reserve requirement ratio cuts and interest rate reductions [2] - The recent US-China trade negotiations have led to a temporary reduction in tariffs, with the US reducing tariffs on Chinese imports from 145% to 30%, and China reducing tariffs on US imports from 125% to 10% for a 90-day period [2] - The Hang Seng Index's valuation has returned to reasonable levels, requiring significant positive developments in trade agreements and corporate earnings improvements to maintain upward momentum [2] Short-term Sector Outlook - Focus on China's fixed asset investment, industrial output, and retail sales for January to May, as well as the performance of specific companies like Café de Coral Group [3] Macro Focus - In May, new loans in mainland China amounted to 620 billion RMB, falling short of expectations, with total new loans for the first five months reaching 10.68 trillion RMB [4][9] - The People's Bank of China reported a year-on-year increase of 7.9% in M2 money supply, while M1 increased by 2.3% [9] - The social financing scale increased by 2.29 trillion RMB in May, with a cumulative increase of 18.63 trillion RMB for the first five months [9] Company News - Strategic research cooperation agreement established between CSPC Pharmaceutical Group and AstraZeneca [4] - WuXi Biologics' major shareholder reduced holdings at a discount, realizing 2.2 billion RMB [4] - Zijin Mining lowered production guidance for the Kakula copper mine, impacting this year's profits [4] International Market Outlook - The US Federal Reserve maintained interest rates, with expectations of two rate cuts totaling 0.5% this year, reflecting increased uncertainty in the economic outlook [4] - OPEC+ is increasing supply, exacerbating supply-demand imbalances and limiting upward pressure on international oil prices [4] Technology Sector - Apple iPhone sales in China rose to first place in May, with a year-on-year global sales growth of 15% during April and May, marking the strongest performance since the pandemic [10]

藥明生物(02269)表現強勢，截至14點20分，股價報26.4元，升幅1.54%，資金持續流入。技術面上，RSI升至67，接近超買區，但MACD及一目均衡表仍釋出 買入訊號，短線動能強勁。目前關鍵阻力位在27.5元，若突破則有望挑戰29元；下方支撐位24.7元，若回調至此可視為低吸機會。 技術分析：多頭格局穩固，短線關注突破 藥明生物近期走勢呈現築底回升，10日、30日及60日均線（25.09、23.98、23.91元）呈多頭排列，顯示中期趨勢向好。MACD黃金交叉後持續擴張，保力加 通道亦顯示股價沿上軌運行，短線仍有上行空間。不過，RSI已接近70超買水準，投資者需留意若股價未能突破27.5元，可能面臨短線獲利回吐壓力。 技術 信號總結為"買入"其中有3個賣出信號，6個中立信號以及15個買入信號。 窩輪產品回顧 在2025年6月6日，藥明生物正股兩日內上漲7.1%，相關窩輪產品表現強勁。其中，瑞銀牛證（56751）漲幅最高，達43%，摩通牛證（57118）緊隨其後，上 漲38%。兩只認購證漲幅相對較低，摩利認購證（14687）和中銀認購證（15841）分別上漲11%和22%。 窩輪與牛熊證機會：高槓桿捕捉 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 自願公告 注射用HLX43（靶向PD-L1抗體偶聯藥物）用於治療晚期非小細胞肺癌 (NSCLC)的國際多中心2期臨床研究於中國境內完成首例患者給藥 A. 緒言 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知 本公司股東及潛在投資者本公司最新業務更新。 本公司董事會（「董事會」）欣然宣佈，近日，一項注射用HLX43（靶向PD-L1 抗體偶聯藥物）（「HLX43」）在晚期非小細胞肺癌(NSCLC)患者中開展的國際 多中心2期臨床研究於中國境內（不包括中國港澳台地區，下同）完成首例患 者給藥。 B. 臨床試驗設計及目的 HLX43是由本公司利用自蘇州宜聯生物醫藥有限公司許可引進的新型DNA拓 撲異構酶I抑制劑小分子毒素－肽鏈連 ...